1.2 Billion Heavy Blow! Blue Sailing Medical Joins Forces with Thai Capital, Completely Penetrating Glove Industry Chain?

Listing | Zhongfang.com

Review | Li Xiaoyan

As the global trade landscape is reshaped and the disposable protective glove industry undergoes deep cleanup, supply and demand are entering a critical recovery phase. At the intersection of industry cycles and corporate strategy, Blue Sail Medical (002382.SZ) abandons extensive “new capacity expansion” and adopts a combination of 1.2 billion yuan in existing asset integration plus Thai industrial capital investment to complete the reshaping of the health protection business supply chain. On March 12, 2026, the company announced the completion of two core acquisitions, with payments and business registration changes finalized, marking the realization of integrated nitrile glove capacity and energy security. The energy shortfall that has long constrained profitability has been fully addressed, and the main health protection business enters a new stage of large-scale, intensive development.

This integration is led by Blue Sail Medical’s controlling subsidiary, Shandong Blue Sail Health Technology Co., Ltd., with a total investment of 1.2 billion yuan, divided into two core segments. First, 800 million yuan was used to acquire 100% equity of Zibo Blue Sail Health Technology and Zibo Blue Sail Protective Products, consolidating the two nitrile glove manufacturing entities, shifting the operating entity from foreign to domestic ownership, and optimizing registered capital to 627 million yuan, clarifying ownership and operational structure. Second, 400 million yuan was used to acquire an 80% stake in Zibo Hongda Thermal Power from the actual controller and related parties, integrating key energy assets into consolidated financial statements. While related-party transactions, these do not involve major asset restructuring. Both transactions are funded by a $200 million capital injection from Thai industrial investor HKG in June 2024, not using the listed company’s own funds, achieving industry integration while safeguarding cash flow.

The entry of Thai industrial capital is a key strategic pivot. HKG, a Thai industrial holding group with over 40 years of history, has formed a deep partnership with Blue Sail Medical from a long-term industrial investment perspective. The first capital injection was successfully received in July 2024. Both parties agreed to use Shandong Health Technology as a platform to develop a cross-regional, risk-resistant, high-quality multinational joint venture. Supported by Thai capital and industrial resources, Blue Sail Medical has completed the integration of nitrile glove capacity and energy asset acquisition in one go, achieving strategic synergy of “production + energy,” breaking through previous bottlenecks of dispersed capacity, external energy procurement, and high costs. After the transaction, the three major nitrile manufacturing bases will coordinate equipment deployment, process optimization, and supply chain management, significantly improving production planning, supply chain stability, and market responsiveness, laying a solid foundation for scale expansion.

Addressing energy shortages is the most strategically valuable breakthrough of this integration. Nitrile glove production is energy-intensive, with energy costs such as electricity and steam accounting for 15%-25% of total costs. External energy procurement not only raises production costs but also depends on market prices and supply stability. Blue Sail Medical Chairman Liu Wenjing clearly stated in an industry briefing that Thai investors helped integrate Hongda Thermal Power and added new combined heat and power (CHP) facilities, thoroughly solving energy supply issues. Hongda Thermal Power, a regional core CHP enterprise, was already a key energy supplier for the company’s glove bases. After acquisition, it achieves energy self-sufficiency, stabilizing supply and reducing costs. Additionally, leveraging foreign investment cooperation, it obtained a rare new CHP license, enabling external power and heat supply on top of self-use, creating incremental revenue streams. Meanwhile, the company’s CHP assets in Weifang and Zibo form a dual energy security pattern, with full industry chain cost control capabilities ranking among the top in the industry.

From a financial and operational perspective, this integration brings multiple positive effects. First, energy self-sufficiency significantly reduces unit costs of nitrile gloves, greatly enhancing cost competitiveness and offsetting raw material price increases, directly boosting gross margins. Second, equity sales and asset integration provide direct cash inflows, optimize the asset-liability structure, and ease previous financial pressures from losses. Third, internal capacity consolidation reduces related-party transactions, improves operational transparency and management efficiency, and the foreign-investor background further supports overseas market expansion, aligning with global trade adjustments. Currently, the company’s nitrile and PVC glove capacities of about 25 billion pairs each are fully operational and sold out. In Q4 2025, glove gross profit margins turn positive, with continued narrowing of losses. A performance turnaround in 2026 is expected, driven by synergistic effects of costs, prices, and capacity.

From an industry perspective, Blue Sail Medical’s strategic integration precisely aligns with the industry recovery cycle. Between 2022 and 2024, the global glove industry experienced overcapacity and depressed prices, leading to accelerated cleanup of lagging capacity and near completion of downstream inventory destocking. Since 2025, supply and demand have continued to improve, with nitrile gloves replacing latex and PVC gloves due to their low allergenicity and high protection, steadily releasing demand in medical, industrial, and food processing sectors, with product prices beginning to rise. Against this backdrop, Blue Sail Medical reduces costs and improves efficiency through existing capacity integration rather than adding new capacity, aligning with supply-side optimization and seizing cyclical recovery benefits, forming core competitiveness based on “cost advantage + scale effect + channel barriers.”

While the positive value is evident, potential challenges remain. First, the industry recovery pace is uncertain; if global demand recovers slower than expected or prices do not rebound strongly, profit margins from cost optimization may be limited. Second, Hongda Thermal Power, as a related-party acquisition target, requires ongoing regulation to ensure fair pricing and avoid利益输送 risks. Third, managing cross-cultural differences and resource coordination in the Thai joint venture, as well as the construction progress and profitability of new CHP projects, will need time to verify. Additionally, the company’s health protection business is expected to incur losses in 2025 due to operational, tax, and asset impairment factors, with a turnaround in 2026 relying on coordinated improvements in costs, prices, and capacity, meaning short-term performance may still fluctuate.

Overall, Blue Sail Medical’s strategic layout of 1.2 billion yuan in integration plus Thai capital empowerment is a long-term, precise move to break through key bottlenecks. During the critical period of global glove industry reshaping, the company opts for stock-based consolidation instead of capacity expansion, addresses energy supply gaps through industry chain integration, and enhances risk resistance via international capital cooperation. This not only solves current profitability issues but also builds long-term competitive barriers. As energy cost advantages are released, capacity synergy emerges, and industry cycles turn upward, Blue Sail Medical’s health protection business is expected to achieve a fundamental shift from loss to profit, becoming a core growth driver for the company’s 2026 performance recovery.

Looking ahead, with the full deployment of CHP assets, increased high-end glove production, and expansion into overseas markets, Blue Sail Medical will further consolidate its leading position in the industry, achieving high-quality development through the synergy of “health protection + cardiovascular and cerebrovascular” main businesses. For the recovering protective glove industry, Blue Sail Medical’s integration path also provides a model for “cost reduction, quality improvement, and efficiency enhancement,” promoting a shift from price competition to value competition within the industry.